Form 4: Director's Options Converted in scPharmaceuticals Merger

A director of scPharmaceuticals Inc. converted all outstanding stock options into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.

Summary

• Reporting Person Minnie Baylor-Henry, a director of scPharmaceuticals Inc., disposed of all her derivative securities (stock options) on October 7, 2025.
• This transaction occurred in connection with the Agreement and Plan of Merger, dated August 24, 2025, between scPharmaceuticals Inc., MannKind Corporation, and Seacoast Merger Sub, Inc.
• Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of MannKind Corporation, completed a tender offer for shares of scPharmaceuticals' common stock on October 7, 2025.
• Each outstanding and unexercised stock option with an exercise price less than $5.35 was cancelled and converted into a cash payment and one Contingent Value Right (CVR) per share.
• The cash payment was calculated as the total number of shares subject to such option multiplied by the excess of $5.35 over the option's exercise price.

Sentiment

Score: 7

Explanation: The filing reports the expected execution of a merger agreement, where a director's stock options were converted into cash and CVRs. This is a standard and anticipated outcome of an acquisition, providing a defined value for existing equity incentives.

Positives

• The merger provides a clear exit strategy and liquidity for option holders with in-the-money options.
• Option holders receive immediate cash for the intrinsic value of their options based on the $5.35 per share merger consideration.
• The inclusion of Contingent Value Rights (CVRs) offers potential future upside based on specific, undisclosed contingencies related to the merger.

Negatives

• The director no longer holds direct equity-linked incentives in scPharmaceuticals Inc., as the company is being acquired.
• The original stock options are cancelled, meaning no future upside from the original options beyond the fixed $5.35 per share cash component and the CVRs.

Risks

• The value of the Contingent Value Rights (CVRs) is contingent and not guaranteed, representing a potential future challenge if the underlying conditions for payout are not met.

Future Outlook

The filing indicates the completion of a tender offer and the conversion of options in anticipation of a merger, suggesting scPharmaceuticals Inc. will become a subsidiary of MannKind Corporation. The future outlook for scPharmaceuticals as an independent entity is limited, with its operations likely integrated into MannKind. The Contingent Value Rights (CVRs) represent a potential future payout based on specific, undisclosed contingencies.

Management Comments

• The cancellation and conversion of stock options were executed in accordance with the terms of the Agreement and Plan of Merger, dated August 24, 2025, following the completion of the tender offer on October 7, 2025.

Industry Context

This transaction is typical for a company undergoing an acquisition, reflecting consolidation within the pharmaceutical or biotechnology sector. Larger companies often acquire smaller ones for their pipeline, technology, or market access. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps or share future risks and rewards.

Comparison to Industry Standards

• The use of a tender offer followed by a merger agreement is a standard M&A process in the pharmaceutical and biotechnology industries.
• The conversion of in-the-money stock options into cash and CVRs is a common practice in acquisitions to ensure all equity stakeholders are appropriately compensated and aligned with the transaction terms.
• The $5.35 per share cash component for options is a specific deal term, comparable to other M&A transactions where a fixed cash price is offered for outstanding equity.

Corporate Governance

Related Party Transactions

• The disposition of stock options by Director Minnie Baylor-Henry is a related-party transaction executed as part of the broader merger agreement between scPharmaceuticals Inc. and MannKind Corporation.

Stakeholder Impact

• Shareholders who tendered their shares received cash consideration as part of the tender offer.
• Option holders, including Director Minnie Baylor-Henry, received cash for the intrinsic value of their options and Contingent Value Rights.
• Employees with stock options would also be subject to similar conversion terms, impacting their equity compensation structure.
• Directors, such as Minnie Baylor-Henry, had their equity incentives converted, aligning their financial interests with the merger outcome.

Next Steps

• Integration of scPharmaceuticals Inc. into MannKind Corporation following the completion of the merger.
• Realization of value from Contingent Value Rights based on their specific terms and the achievement of underlying contingencies.

Key Dates

Keywords

scPharmaceuticals, SCPH, MannKind Corporation, Merger, Tender Offer, Stock Options, Form 4, Director, Contingent Value Rights, CVR